Immunic/IMUX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Immunic

Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.

Ticker

IMUX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

Headquarters

New york, United States

Employees

77
Website
imux.com

Immunic Metrics

BasicAdvanced
$112M
Market cap
-
P/E ratio
-$1.84
EPS
1.83
Beta
-
Dividend rate
$112M
1.83
$3.11
$0.95
7
5.094
-91.94%
-112.05%
-110.91%
1.336
1.336
47.03%

What the Analysts think about Immunic

Analyst Ratings

Majority rating from 5 analysts.
Buy

Immunic Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$30M
37.21%
Profit margin
0.00%
NaN%

Immunic Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 15.38%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.54
-$0.51
-$0.48
-$0.30
-
Expected
-$0.52
-$0.55
-$0.51
-$0.26
-$0.23
Surprise
3.05%
-6.85%
-6.48%
15.38%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Immunic stock?

Immunic (IMUX) has a market cap of $112M as of June 25, 2024.

What is the P/E ratio for Immunic stock?

The price to earnings (P/E) ratio for Immunic (IMUX) stock is 0 as of June 25, 2024.

Does Immunic stock pay dividends?

No, Immunic (IMUX) stock does not pay dividends to its shareholders as of June 25, 2024.

When is the next Immunic dividend payment date?

Immunic (IMUX) stock does not pay dividends to its shareholders.

What is the beta indicator for Immunic?

Immunic (IMUX) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Immunic stock price target?

The target price for Immunic (IMUX) stock is $11.5, which is NaN% below the current price of $. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Immunic stock

Buy or sell Immunic stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing